Recently, in another study, LBL-007, a new anti-LAG-3 IgG4 antibody, was assessed in mice with CRC at a dose of 10 mg/kg twice a week for three weeks; it was found to inhibit tumor growth. Here, LAG3 is linked to neoplasm.